Gapping up
In reaction to strong earnings/guidance: ZOES +4.5%, DMND +3.7%, CMGE +2.2%, UTIW +1.3%, ALOG +0.5%
M&A news: JASO +14.4% (receives non-binding 'going private' proposal for $9.69/share from Chairman and CEO), INO +2.4% (hearing reports of takeover rumors), LBTYA +1% (reports AMC that co is in discussions with Vodafone (VOD) regarding a potential transaction)
Other news: PTN +60% (positive FDA panel vote for Sprout Pharma's (private company) filbanserin for the treatment of hypoactive sexual desire disorder in premenopausal women ), PACD +9.7% (still checking, may be OPEC related), ARO +5% (CEO disclosed purchase of 250K shares, worth total of $481.1K; 6/3-6/4 transaction dates), CETV +4.5% (still checking), LTBR +4.1% (announces South Korea granted patent for metallic nuclear fuel design), RTRX +3% (received fast track designation for RE-024 for the treatment of pantothenate kinase-associated neurodegeneration), ISIS +3% (license agreement with Bayer HealthCare (BAYRY) for ISIS-FXIRx has cleared the HSR period, resulting in immediate payment to Isis of $100 mln), OPXA +2.9% (disclosed that NASDAQ granted extension request; co now has until November 30, 2015 to regain compliance with the minimum bid requirement), ANTH +2.6% (announces additional data on patient-reported outcomes from Phase 2b PEARL-SC Blisibimod study; Treatment with blisibimod was associated with statistically significant and clinically meaningful improvements in patient-reported fatigue (, MANH +2.6% (to replace LTM in the S&P MidCap 400), FEYE +1.9% (after US Office of Personnel Mgmt security breach), HZNP +1.4% (announces initiation of a Phase 3 trial of Actimmune, to treat of patients with Friedreich's Ataxia), PANW +1.3% (after US Office of Personnel Mgmt security breach)
Analyst comments: AES +1.5% (upgraded to Overweight from Neutral at JP Morgan), GRPN +0.8% (reinstated with a Buy at Deutsche Bank)
In reaction to strong earnings/guidance: ZOES +4.5%, DMND +3.7%, CMGE +2.2%, UTIW +1.3%, ALOG +0.5%
M&A news: JASO +14.4% (receives non-binding 'going private' proposal for $9.69/share from Chairman and CEO), INO +2.4% (hearing reports of takeover rumors), LBTYA +1% (reports AMC that co is in discussions with Vodafone (VOD) regarding a potential transaction)
Other news: PTN +60% (positive FDA panel vote for Sprout Pharma's (private company) filbanserin for the treatment of hypoactive sexual desire disorder in premenopausal women ), PACD +9.7% (still checking, may be OPEC related), ARO +5% (CEO disclosed purchase of 250K shares, worth total of $481.1K; 6/3-6/4 transaction dates), CETV +4.5% (still checking), LTBR +4.1% (announces South Korea granted patent for metallic nuclear fuel design), RTRX +3% (received fast track designation for RE-024 for the treatment of pantothenate kinase-associated neurodegeneration), ISIS +3% (license agreement with Bayer HealthCare (BAYRY) for ISIS-FXIRx has cleared the HSR period, resulting in immediate payment to Isis of $100 mln), OPXA +2.9% (disclosed that NASDAQ granted extension request; co now has until November 30, 2015 to regain compliance with the minimum bid requirement), ANTH +2.6% (announces additional data on patient-reported outcomes from Phase 2b PEARL-SC Blisibimod study; Treatment with blisibimod was associated with statistically significant and clinically meaningful improvements in patient-reported fatigue (, MANH +2.6% (to replace LTM in the S&P MidCap 400), FEYE +1.9% (after US Office of Personnel Mgmt security breach), HZNP +1.4% (announces initiation of a Phase 3 trial of Actimmune, to treat of patients with Friedreich's Ataxia), PANW +1.3% (after US Office of Personnel Mgmt security breach)
Analyst comments: AES +1.5% (upgraded to Overweight from Neutral at JP Morgan), GRPN +0.8% (reinstated with a Buy at Deutsche Bank)